Can-Fite BioPharma is an Israeli biopharmaceutical company with fully integrated pharmaceutical discovery and clinical development capabilities. The company has an advanced pipeline of proprietary drug candidates in phase II and phase III clinical development that address inflammatory, liver, and metabolic diseases. Can-Fite's platform technology utilizes the Gi protein-associated A3 adenosine receptor (A3AR) as a therapeutic target. A3AR is highly expressed in inflammatory, cancer, and other pathological body cells, whereas low expression is found in normal cells, suggesting that the receptor could be a unique target for pharmacological intervention. The company's compounds bind with nM affinity to the A3AR and initiate deregulation of the NF-kB and Wnt signal transduction pathways, resulting in anti-inflammatory and anticancer effects.